As on Wednesday, Abbott Laboratories (NYSE: ABT) got off with the flyer as it spiked 3.21% to $107.26, before settling in for the price of $103.92 at the close. Taking a more long-term approach, ABT posted a 52-week range of $89.67-$121.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 6.10%. Meanwhile, its Annual Earning per share during the time was 19.65%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 4.91%. This publicly-traded company’s shares outstanding now amounts to $1.73 billion, simultaneously with a float of $1.73 billion. The organization now has a market capitalization sitting at $186.59 billion. At the time of writing, stock’s 50-day Moving Average stood at $103.87, while the 200-day Moving Average is $106.70.
Abbott Laboratories (ABT) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Medical Devices industry. Abbott Laboratories’s current insider ownership accounts for 0.72%, in contrast to 79.14% institutional ownership. According to the most recent insider trade that took place on May 10 ’24, this organization’s EXECUTIVE VICE PRESIDENT sold 10,097 shares at the rate of 104.57, making the entire transaction reach 1,055,819 in total value, affecting insider ownership by 211,341. Preceding that transaction, on May 07 ’24, Company’s EXECUTIVE VICE PRESIDENT sold 22,852 for 106.25, making the whole transaction’s value amount to 2,428,119. This particular insider is now the holder of 61,462 in total.
Abbott Laboratories (ABT) Earnings and Revenue Records
Abbott Laboratories’s EPS increase for this current 12-month fiscal period is 4.91% and is forecasted to reach 5.14 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 8.10% through the next 5 years, which can be compared against the 19.65% growth it accomplished over the previous five years trading on the market.
Abbott Laboratories (NYSE: ABT) Trading Performance Indicators
Let’s observe the current performance indicators for Abbott Laboratories (ABT). It’s Quick Ratio in the last reported quarter now stands at 1.11. The Stock has managed to achieve an average true range (ATR) of 2.05. Alongside those numbers, its PE Ratio stands at $33.82, and its Beta score is 0.72. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.58. Similarly, its price to free cash flow for trailing twelve months is now 37.90.
In the same vein, ABT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 3.17, a figure that is expected to reach 1.20 in the next quarter, and analysts are predicting that it will be 5.14 at the market close of one year from today.
Technical Analysis of Abbott Laboratories (ABT)
Through scrutinizing the latest numbers posted by the [Abbott Laboratories, ABT], it can be observed that its last 5-days Average volume of 9.5 million was better the volume of 5.85 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 79.24% While, its Average True Range was 2.19.
Raw Stochastic average of Abbott Laboratories (ABT) in the period of the previous 100 days is set at 34.43%, which indicates a major fall in contrast to 99.34% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 29.84% that was higher than 19.55% volatility it exhibited in the past 100-days period.
